147 related articles for article (PubMed ID: 10760333)
1. Minimal heparinization in coronary angioplasty--how much heparin is really warranted?
Kaluski E; Krakover R; Cotter G; Hendler A; Zyssman I; Milovanov O; Blatt A; Zimmerman E; Goldstein E; Nahman V; Vered Z
Am J Cardiol; 2000 Apr; 85(8):953-6. PubMed ID: 10760333
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
[TBL] [Abstract][Full Text] [Related]
3. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
[TBL] [Abstract][Full Text] [Related]
4. Safety of low dose heparin in elective coronary angioplasty.
Koch KT; Piek JJ; de Winter RJ; David GK; Mulder K; Tijssen JG; Lie KI
Heart; 1997 Jun; 77(6):517-22. PubMed ID: 9227294
[TBL] [Abstract][Full Text] [Related]
5. Heparin dosing for percutaneous coronary angioplasty: use of body surface area to improve initial activated clotting time values.
Pesola GR; Pesola DA
Clin Cardiol; 1997 Dec; 20(12):1006-9. PubMed ID: 9422838
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive intracoronary urokinase therapy during percutaneous transluminal coronary angioplasty.
Schächinger V; Kasper W; Zeiher AM
Am J Cardiol; 1996 Jun; 77(14):1174-8. PubMed ID: 8651091
[TBL] [Abstract][Full Text] [Related]
7. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
Schächinger V; Allert M; Kasper W; Just H; Vach W; Zeiher AM
Circulation; 1994 Nov; 90(5):2258-66. PubMed ID: 7955182
[TBL] [Abstract][Full Text] [Related]
9. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
[TBL] [Abstract][Full Text] [Related]
10. An open design, multicentre, randomized trial of percutaneous transluminal coronary angioplasty versus stenting, with a heparin-coated stent, of totally occluded coronary arteries: rationale, trial design and baseline patient characteristics. Total Occlusion Study of Canada (TOSCA) Investigators.
Dzavik V; Carere RG; Teo KK; Knudtson ML; Marquis JF; Buller CE
Can J Cardiol; 1998 Jun; 14(6):825-32. PubMed ID: 9676168
[TBL] [Abstract][Full Text] [Related]
11. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty. Clinical and procedural predictors. Heparin Registry Investigators.
Wolfe MW; Roubin GS; Schweiger M; Isner JM; Ferguson JJ; Cannon AD; Cleman M; Cabin H; Leya F; Bonan R
Circulation; 1995 Aug; 92(3):311-9. PubMed ID: 7634443
[TBL] [Abstract][Full Text] [Related]
12. [Single-center experience with the Palmaz-Schatz intracoronary stent: the immediate results and medium- and long-term follow-up].
Galassi AR; Tamburino C; Grassi R; Monaco A; Russo G; Ierna SM; Calvi V; Giuffrida G
Cardiologia; 1996 Nov; 41(11):1097-105. PubMed ID: 9064207
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
[TBL] [Abstract][Full Text] [Related]
14. Immediate femoral sheath removal after 6 French routine coronary angioplasty with a weight-adjusted low-dose heparin: results of a prospective registry.
Metz D; Brasselet C; Tabet E; Nazeyrollas P; Tassan-Mangina S; Deschildre A; Elaerts J; Blaise C
J Invasive Cardiol; 1999 Jul; 11(7):416-20. PubMed ID: 10745564
[TBL] [Abstract][Full Text] [Related]
15. Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.
Rodriguez A; Rodríguez Alemparte M; Fernández Pereira C; Sampaolesi A; da Rocha Loures Bueno R; Vigo F; Obregón A; Palacios IF;
Am J Med; 2005 Jul; 118(7):743-51. PubMed ID: 15989908
[TBL] [Abstract][Full Text] [Related]
16. Laser balloon angioplasty combined with local intracoronary heparin therapy: immediate and short-term follow-up results.
Glazier JJ; Jiang AJ; Crilly RJ; Spears JR
Am Heart J; 1997 Aug; 134(2 Pt 1):266-73. PubMed ID: 9313607
[TBL] [Abstract][Full Text] [Related]
17. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial).
Preisack MB; Bonan R; Meisner C; Eschenfelder V; Karsch KR
Eur Heart J; 1998 Aug; 19(8):1232-8. PubMed ID: 9740345
[TBL] [Abstract][Full Text] [Related]
18. Acute and one year follow-up results after vessel size adapted PTCA using intracoronary ultrasound.
Haase KK; Athanasiadis A; Mahrholdt H; Treusch A; Wullen B; Jaramillo C; Baumbach A; Voelker W; Meisner C; Karsch KR
Eur Heart J; 1998 Feb; 19(2):263-72. PubMed ID: 9519320
[TBL] [Abstract][Full Text] [Related]
19. Adequate heparinization during PTCA: assessment using activated clotting times.
Ogilby JD; Kopelman HA; Klein LW; Agarwal JB
Cathet Cardiovasc Diagn; 1989 Dec; 18(4):206-9. PubMed ID: 2605621
[TBL] [Abstract][Full Text] [Related]
20. Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.
Helft G; Choktron S; Beygui F; Le Feuvre C; Elalamy I; Metzger JP; Vacheron A; Samama MM
Cathet Cardiovasc Diagn; 1998 Nov; 45(3):329-31. PubMed ID: 9829899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
